{
    "xml": "<topic id=\"PHP6107\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/cinacalcet\" basename=\"cinacalcet\" title=\"CINACALCET\">\n<title>CINACALCET</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1022\" namespace=\"/interactions/list-of-drug-interactions/cinacalcet\">Cinacalcet</xref>\n</p>\n<data name=\"vtmid\">409391006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_116785998\" title=\"Calcimimetic agents\">Calcimimetic agents</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP65899\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/cinacalcet\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Cinacalcet reduces parathyroid hormone which leads to a decrease in serum calcium concentrations.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65872\" outputclass=\"indicationsAndDose\" rev=\"1.17\" parent=\"/drugs/cinacalcet\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Secondary hyperparathyroidism in patients with end-stage renal disease on dialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 30&#8239;mg once daily, dose to be adjusted every 2&#8211;4 weeks; maximum 180&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of hypercalcaemia in parathyroid carcinoma</p>\n<p outputclass=\"therapeuticIndication\">Primary hyperparathyroidism in patients where parathyroidectomy is inappropriate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 30&#8239;mg twice daily (max. per dose 90&#8239;mg 4 times a day), dose to be adjusted every 2&#8211;4 weeks according to response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65922\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/cinacalcet\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Treatment should not be initiated in patients with hypocalcaemia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65867\" outputclass=\"interactions\" rev=\"1.15\" parent=\"/drugs/cinacalcet\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (cinacalcet).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65812\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/cinacalcet\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anorexia</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">reduced testosterone concentrations</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">seizures</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Allergic reactions</ph>; <ph outputclass=\"sideEffect\">angioedema</ph>; <ph outputclass=\"sideEffect\">heart failure</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65863\" outputclass=\"pregnancy\" parent=\"/drugs/cinacalcet\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65930\" outputclass=\"breastFeeding\" parent=\"/drugs/cinacalcet\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65890\" outputclass=\"hepaticImpairment\" parent=\"/drugs/cinacalcet\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in moderate to severe impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Monitor closely in hepatic impairment especially when increasing dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65786\" outputclass=\"monitoringRequirements\" parent=\"/drugs/cinacalcet\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Measure serum-calcium concentration before initiation of treatment and within 1 week after starting treatment or adjusting dose, then monthly for secondary hyperparathyroidism, and every 2&#8211;3 months for primary hyperparathyroidism and parathyroid carcinoma.</p>\n<p>In secondary hyperparathyroidism measure parathyroid hormone concentration 1&#8211;4 weeks after starting treatment or adjusting dose, then every 1&#8211;3 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65771\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/cinacalcet\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA117</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (January 2007)</p>\r\n<p>Cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.</p>\r\n<p>Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis <b>only</b> in those:</p>\r\n<ul>\r\n<li>who have 'very uncontrolled' plasma concentration of intact parathyroid hormone (defined as greater than 85&#8239;picomol/litre) refractory to standard therapy, and a normal or high adjusted serum calcium concentration, <b>and</b>\r\n</li>\r\n<li>in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery outweigh the benefits.</li>\r\n</ul>\r\n<p>Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma concentration of intact parathyroid hormone of 30% or greater is seen within 4 months of treatment.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA117\">www.nice.org.uk/TA117</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP6107-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/cinacalcet\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77840\" title=\"Tablet\" namespace=\"/drugs/cinacalcet/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78314\" namespace=\"/treatment-summaries/bone-metabolism\" title=\"Bone metabolism\" count=\"1\" rel=\"backlink\">Bone metabolism</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"1\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1022\" namespace=\"/interactions/list-of-drug-interactions/cinacalcet\" title=\"Cinacalcet\" count=\"1\" rel=\"link\">Cinacalcet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77840\" namespace=\"/drugs/cinacalcet/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP6107",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/cinacalcet",
    "basename": "cinacalcet",
    "title": "CINACALCET",
    "interactants": [
        {
            "id": "bnf_int_1022",
            "label": "Cinacalcet"
        }
    ],
    "vtmid": "409391006",
    "drugClassification": [
        "Calcimimetic agents"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Cinacalcet reduces parathyroid hormone which leads to a decrease in serum calcium concentrations.",
                "html": "<p>Cinacalcet reduces parathyroid hormone which leads to a decrease in serum calcium concentrations.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Secondary hyperparathyroidism in patients with end-stage renal disease on dialysis",
                        "html": "Secondary hyperparathyroidism in patients with end-stage renal disease on dialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 30 mg once daily, dose to be adjusted every 2&#8211;4 weeks; maximum 180 mg per day.",
                        "html": "<p>Initially 30&#8239;mg once daily, dose to be adjusted every 2&#8211;4 weeks; maximum 180&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of hypercalcaemia in parathyroid carcinoma",
                        "html": "Treatment of hypercalcaemia in parathyroid carcinoma"
                    },
                    {
                        "textContent": "Primary hyperparathyroidism in patients where parathyroidectomy is inappropriate",
                        "html": "Primary hyperparathyroidism in patients where parathyroidectomy is inappropriate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 30 mg twice daily (max. per dose 90 mg 4 times a day), dose to be adjusted every 2&#8211;4 weeks according to response.",
                        "html": "<p>Initially 30&#8239;mg twice daily (max. per dose 90&#8239;mg 4 times a day), dose to be adjusted every 2&#8211;4 weeks according to response.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Treatment should not be initiated in patients with hypocalcaemia",
                "html": "Treatment should not be initiated in patients with hypocalcaemia"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (cinacalcet).",
                "html": "<p>Appendix 1 (cinacalcet).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anorexia",
                        "html": "Anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "reduced testosterone concentrations",
                        "html": "reduced testosterone concentrations",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Diarrhoea",
                        "html": "Diarrhoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "seizures",
                        "html": "seizures",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Allergic reactions",
                        "html": "Allergic reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "angioedema",
                        "html": "angioedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "heart failure",
                        "html": "heart failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in moderate to severe impairment.",
                "html": "<p>Manufacturer advises caution in moderate to severe impairment.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor closely in hepatic impairment especially when increasing dose.",
                "html": "<p>Monitor closely in hepatic impairment especially when increasing dose.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Measure serum-calcium concentration before initiation of treatment and within 1 week after starting treatment or adjusting dose, then monthly for secondary hyperparathyroidism, and every 2&#8211;3 months for primary hyperparathyroidism and parathyroid carcinoma.\n\nIn secondary hyperparathyroidism measure parathyroid hormone concentration 1&#8211;4 weeks after starting treatment or adjusting dose, then every 1&#8211;3 months.",
                "html": "<p>Measure serum-calcium concentration before initiation of treatment and within 1 week after starting treatment or adjusting dose, then monthly for secondary hyperparathyroidism, and every 2&#8211;3 months for primary hyperparathyroidism and parathyroid carcinoma.</p><p>In secondary hyperparathyroidism measure parathyroid hormone concentration 1&#8211;4 weeks after starting treatment or adjusting dose, then every 1&#8211;3 months.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA117",
                        "label": "www.nice.org.uk/TA117"
                    }
                ],
                "fundingIdentifier": "NICE TA117",
                "textContent": "Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (January 2007) Cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis only in those: who have 'very uncontrolled' plasma concentration of intact parathyroid hormone (defined as greater than 85 picomol/litre) refractory to standard therapy, and a normal or high adjusted serum calcium concentration, and in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery outweigh the benefits. Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma concentration of intact parathyroid hormone of 30% or greater is seen within 4 months of treatment.\n\nwww.nice.org.uk/TA117",
                "html": "<p outputclass=\"title\">Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (January 2007)</p> <p>Cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.</p> <p>Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis <b>only</b> in those:</p> <ul> <li>who have 'very uncontrolled' plasma concentration of intact parathyroid hormone (defined as greater than 85&#8239;picomol/litre) refractory to standard therapy, and a normal or high adjusted serum calcium concentration, <b>and</b> </li> <li>in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery outweigh the benefits.</li> </ul> <p>Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma concentration of intact parathyroid hormone of 30% or greater is seen within 4 months of treatment.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA117\">www.nice.org.uk/TA117</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77840",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78314",
                "label": "Bone metabolism",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1022",
                "label": "Cinacalcet",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77840",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}